Greenwich LifeSciences, Inc.
NASDAQ:GLSI
13.81 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Greenwich LifeSciences, Inc. |
Symbool | GLSI |
Munteenheid | USD |
Prijs | 13.81 |
Beurswaarde | 181,528,307 |
Dividendpercentage | 0% |
52-weken bereik | 8 - 21.44 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Snehal S. Patel |
Website | https://greenwichlifesciences.com |
An error occurred while fetching data.
Over Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)